Akin Gump Advises Pharmakon Advisors on $350M Term Loan to Insmed

(New York) – Akin Gump pledged $350 million senior collateral to global company Insmed Incorporated (Nasdaq: INSM) to Pharmakon Advisors, LP, a leading investor in non-dilutive bonds for the life sciences industry Advised on a Term Loan (Term Loan). is a biopharmaceutical company with a mission to transform the lives of patients with serious and rare diseases.

The 5-year term loan will mature in October 2027. The Term Loan bears interest at a rate based on the Secured Overnight Finance Rate (SOFR), subject to a 2.5% SOFR floor, in addition to a 7.75% annualized margin. The Term Loan, along with other strategic financings, will have all assets governed by the terms of an inter-credit agreement executed between BioPharma Credit PLC, Orvimed Loyalty & Credit Opportunity IV, LP, and Insmed as collateral agents. Secured by a collateral package.

Click for more information on the deal. here.

The trading team was led by a tax partner Jeffrey Secor Including Senior Counsel Miriam Foley associate with Diandra Molina.

Akin Gump Strauss Hauer & Feld LLP is a leading international law firm with over 900 attorneys in the United States, Europe, Asia and the Middle East.

# # #

Leave a Comment